Viral hepatitis

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Retrieved on: 
Monday, March 18, 2024
Infectious Diseases, Hospitals, Public Policy, Government, Philanthropy, Managed Care, Health, State, Local, General Health, Foundation, Pregnancy, Liver failure, HBI, Organization, University, Hepatitis B, Disease, CDA, Cirrhosis, Patient, Public, HBV, Woman, Viral hepatitis, Medicaid, Liver cancer, Refugee, HCV, Pharmaceutical industry

“CDA Foundation is very proud to have been selected to distribute these grants,” commented Homie Razavi, the Managing Director of CDA Foundation.

Key Points: 
  • “CDA Foundation is very proud to have been selected to distribute these grants,” commented Homie Razavi, the Managing Director of CDA Foundation.
  • “Loss of diagnosed but untreated patients is a major barrier for countries trying to achieve the viral hepatitis elimination targets.
  • The submission window for the second round of proposals opened in February 2024 for programs with a duration of no more than 18 months.
  • For more information, please visit https://cdafound.org/relink or contact CDA Foundation at [email protected] .

Government of Canada releases 2024-2030 Action Plan on Sexually Transmitted and Blood-Borne Infections

Retrieved on: 
Tuesday, February 27, 2024
Inhalation, Violence, Infection, Syphilis, CIHR, AIDS, Federation, Government, Action plan, Metis, Ectopic pregnancy, Viral hepatitis, First Nations, Science, Risk, Housing, Public, Research, Infertility, Cancer, Birth control

OTTAWA, ON, Feb. 27, 2024 /CNW/ - Sexually transmitted and blood-borne infections (STBBI) are largely preventable, treatable, and in many cases curable.

Key Points: 
  • OTTAWA, ON, Feb. 27, 2024 /CNW/ - Sexually transmitted and blood-borne infections (STBBI) are largely preventable, treatable, and in many cases curable.
  • However, rates of sexually transmitted infections in Canada have increased over the last decade—gonorrhea rates have doubled since 2012, and syphilis rates are five times what they were.
  • That is why today, the Honourable Mark Holland, Minister of Health, launched the Government of Canada's sexually transmitted and blood-borne infections (STBBI) action plan 2024-2030 and announced $2.45 million in funding to address STBBI in Canada.
  • The Action Plan will continue to work towards reducing STBBI related stigma, to prevent new and reoccurring infections and connect people to testing, prevention, treatment and care."

bioLytical Laboratories Inc. Donates Tests to Help Boost International Testing Access Ahead of International Testing Week

Retrieved on: 
Wednesday, November 22, 2023
Partnership, HIV/AIDS, Infection, NGO, Health, MDSAP, Coalition, Hepatitis, STI, Public, HIV, Patient, Viral hepatitis, Vaccine

International Testing Week, scheduled for November 22- 28 this year, helps raise awareness of the importance of accessible testing for individual and public health.

Key Points: 
  • International Testing Week, scheduled for November 22- 28 this year, helps raise awareness of the importance of accessible testing for individual and public health.
  • Robert Mackie, CEO, bioLytical, emphasizes the significance of International Testing Week and states, "International Testing Week serves as a global reminder of the critical role rapid testing plays in safeguarding public health.
  • By donating these tests, bioLytical and Coalition PLUS aim to address the disparities in healthcare access and testing capabilities worldwide.
  • In 2022, bioLytical launched iStatis, its new lateral flow testing platform, to create additional access to testing worldwide.

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hepatology, INSERM, Immunity, Interferon, Immune system, ALT, HDV, HBsAg, AASLD, Clinical trial, Viral hepatitis, EOT, Patient, Small RNA, Abstract, Week, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, Peginterferon-alfa, CHD, APHP, Hepatitis, Vir, RNA, Vaccine, Pharmaceutical industry, Communications satellite, Treatment, Medicine

To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.

Key Points: 
  • To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.
  • “Chronic hepatitis delta is the most aggressive form of viral hepatitis.
  • Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:45 p.m. Pacific Time / 4:45 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hepatology, INSERM, Interferon, AASLD, Viral hepatitis, Patient, EOT, Abstract, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, CHD, APHP, Hepatitis, Vaccine, Treatment, Medicine, Boston

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.
  • These include one late-breaking poster presentation and one late-breaking oral presentation.
  • Title: VIR-2218 and VIR-3434 With or Without Pegylated Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results After 24 Weeks of Therapy (March Study Part B) (Abstract #48500)
    Presenter: Edward Gane, M.D., Professor of Medicine at the University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital
    Title: The Monoclonal Antibody VIR-3434 And siRNA VIR-2218 for the Treatment of Chronic Hepatitis D Virus: Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract #5004)
    Presenter: Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, and Head of Viral Hepatitis at INSERM UMR1149, France
    Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Retrieved on: 
Wednesday, November 8, 2023
Research, IND, American Association for the Study of Liver Diseases, International, Infection, HSV, Therapy, Hepatology, Viral, Biotechnology, Liver, Viral hepatitis, Hepatitis D, Doctor of Philosophy, Gilead Sciences, Assembly, Partnership, Virology, Hepatitis B, Patient, HDV, HBV, AASLD, Pharmaceutical industry, Vaccine, Birth control, MD

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond

Key Points: 
  • Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.
  • We believe that the financial and scientific resources provided by the collaboration position us well to reach critical short- and long-term milestones and deliver value for patients and our shareholders.
  • Partnership includes Gilead opt-in rights on Assembly Bio’s current and future pipeline candidates, including two contributed Gilead herpesvirus programs.
  • Cash, cash equivalents and marketable securities were $46.2 million as of September 30, 2023, compared to $59.8 million as of June 30, 2023.

NEW REPORT: Public Health Departments Lack Funding for Hepatitis Surveillance Systems

Retrieved on: 
Friday, November 3, 2023
Associate, Infection, Korea Disease Control and Prevention Agency, Key finding attacks, Public health, White House, Hepatitis, Hepatitis C, Congress, Mortality, Viral hepatitis, Data collection, Local, HIV, Doctor of Philosophy, STD, Data, Data science, FTE, CDC, Gender identity, Disease, Risk, Health equity, Joe Biden, Emory, White, Public, Hepatitis B, D.C, Vaccine, Pharmaceutical industry, Epidemiology

~ HepVu and NASTAD, leading viral hepatitis organizations, release second annual assessment of viral surveillance practices across U.S. jurisdictions ~

Key Points: 
  • ~ HepVu and NASTAD, leading viral hepatitis organizations, release second annual assessment of viral surveillance practices across U.S. jurisdictions ~
    Washington, D.C. – Today, HepVu and NASTAD , leading viral hepatitis organizations, released a new report showing U.S. jurisdictions continue to lack funding and resources needed to effectively implement viral hepatitis surveillance programs.
  • A robust surveillance system allows the U.S. to monitor disease burden and disparities and mount an effective public health response to eliminate viral hepatitis in the U.S.
  • Robust viral hepatitis surveillance systems are critical to guide strategies for prevention and treatment of infections and to reduce viral hepatitis-related disparities and health inequities.
  • Prior to 2021, only 14 states received federal funding specifically for viral hepatitis surveillance.

Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, FDA, ATTR, The New England Journal of Medicine, Science, Therapy, Bachelor of Medicine, Bachelor of Surgery, Cardiomyopathy, Medication, Use, Viral hepatitis, Symantec Endpoint Protection, Conference, American Heart Association, Quarter, Acquisition, Haemophilia, Clinical trial, TTR, Truly Madly Deeply – Ultra Rare Tracks, Growth, Polyneuropathy, Risk, Hypertension, RNA interference, ALN, Roche, Sanofi, Amyloidosis, Patient, APOLLO, ASCVD, Phase 1, Pharmaceutical industry, Video game, Medical device, Aluminium, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Inclisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.
  • Attained over 3,790 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUTTRA as of September 30, 2023.
  • Alnylam announces today that it will present a review of its RNAi platform and pipeline progress at a virtual R&D Day on December 13, 2023.
  • Financial Results for the Quarter Ended September 30, 2023

Children’s Hospital Los Angeles Researchers Develop Clinical Tool to Predict if a Child in Acute Liver Failure Will Need a Transplant

Retrieved on: 
Monday, October 23, 2023
Software, Research, Internet, Family, Consumer, Apps, Applications, Technology, Hospitals, Children, Science, Surgery, Health, Liver injury, Child, Children's Hospital Los Angeles, PELD, Smartphone, Liver, MD, USC, Viral hepatitis, Cirrhosis, Doctor of Philosophy, FRCSC, MBBS, Immune-mediated inflammatory diseases, FACS, King's College Hospital NHS Foundation Trust, Division, Chronic liver disease, Risk, National Cancer Institute, CHLA, Nutrition, Probability, King's College Hospital, Hepatotoxicity, Liver failure, NIH, MHA, Hospital, Patient, Transplant, Acute liver failure, Diagnosis, Death, MS, Dietary supplement, Birth control, Gastroenterology

Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.

Key Points: 
  • Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.
  • While pediatric acute liver failure has been linked to both viral hepatitis and drug-induced liver injury, at least half of cases have no apparent trigger.
  • The CHALF Score predicts if a child experiencing acute liver failure will recover or should be referred to a transplant center.
  • Doctors do not want to refer a child for liver transplant who could otherwise recover with medical treatment—about 70% of children with acute liver failure recover while keeping their original liver.

Findhelp Partners with State of Colorado to Fight Spread of Infectious Diseases

Retrieved on: 
Wednesday, October 18, 2023
Infection, Korea Disease Control and Prevention Agency, Public health, Viral hepatitis, Colorado Department of Labor and Employment, HIV, Colorado Department of Public Health and Environment, Environment, Hepatitis A, Drug, Privacy, Diagnosis, Vaccine

Coloradans trust findhelp to connect them with the social care services they need.

Key Points: 
  • Coloradans trust findhelp to connect them with the social care services they need.
  • Nearly 560,000 users in the state have conducted 1.74 million searches on the findhelp platform.
  • "We are immensely grateful to CDPHE for allowing us to help with this crucial need," said Erine Gray, founder and CEO of findhelp.
  • In 2020, the state suffered an historic high of 1,477 fatal overdoses; in 2022, that number rose to 1,799.